NASDAQ · ELUT
Elutia Inc
$0.80-$0.01 (-1.24%)
Elutia Inc’s quoted price sits in the lower half of its reported 52-week range, 42.19% below the high.
Loading market information…
NASDAQ · STRM · USD
Stock price, earnings
Quote as of Aug 12, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Streamline Health Solutions, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.56% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Streamline Health Solutions, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Streamline Health Solutions, Inc. delivers advanced health information technology platforms and related support services to hospitals and healthcare systems across the United States and Canada. Their product suite encompasses specialized software applications, expert consulting, and meticulous auditing and coding services, all engineered to gather, consolidate, and interpret both structured and unstructured data to generate actionable predictive insights. The company also offers comprehensive solutions for coding and clinical documentation improvement (CDI), which include an integrated cloud-based software package, CDI support, abstracting tools, and physician query functions. Additionally, they provide eValuator, a specialized coding analysis platform, alongside various software services. Their offerings extend to financial management systems, covering accounts receivable, denial resolution, claims processing, expenditure tracking, and audit oversight, as well as patient care tools, Cerner Command Language (CCL) reporting, and custom integration services for CDI/abstracting, staff training, and auditing. Streamline Health Solutions distributes its products and services via an internal sales team and strategic reseller partnerships. Founded in 1989, the company is headquartered in Alpharetta, Georgia.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:28 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $5.36M-2.35% vs estimate |
| Q3 2023 | Dec 14, 2023 | -$0.30+55.56% vs estimate | $6.13M-3.59% vs estimate |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.80-$0.01 (-1.24%)
Elutia Inc’s quoted price sits in the lower half of its reported 52-week range, 42.19% below the high.
$0.29-$0.06 (-17.87%)
Akumin Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.81% below the high.
$0.63$0.00 (0.0%)
LakeShore Biopharma Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 92.71% below the high.
$0.66$0.00 (0.0%)
Invacare Corporation’s quoted price sits in the lower half of its reported 52-week range, 73.92% below the high.
$0.72$0.00 (0.0%)
Cyclo Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.52% below the high.
$0.21+$0.01 (+5.66%)
Renalytix Plc’s quoted price sits in the lower half of its reported 52-week range, 91.37% below the high.
$0.37-$0.01 (-2.12%)
Elevation Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.19% below the high.
$3.10-$0.17 (-5.2%)
PHAXIAM Therapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 76.15% below the high.
